Vincenzo Russo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6810554/publications.pdf

Version: 2024-02-01

235	3,584	172457	276875
papers	citations	29 h-index	41 g-index

242	242	242	3413
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients. Cardiovascular Drugs and Therapy, 2022, 36, 705-712.	2.6	15
2	Acute myocarditis: prognostic role of speckle tracking echocardiography and comparison with cardiac magnetic resonance features. Heart and Vessels, 2022, 37, 121-131.	1.2	9
3	Biventricular dysfunction and lung congestion in athletes on anabolic androgenic steroids: a speckle tracking and stress lung echocardiography analysis. European Journal of Preventive Cardiology, 2022, 28, 1928-1938.	1.8	11
4	The Impact of the COVID-19 Outbreak on Patientsâ€™ Adherence to PCSK9 Inhibitors Therapy. Journal of Clinical Medicine, 2022, 11, 475.	2.4	9
5	Long-Term Prognostic Impact of Right Ventricular Dysfunction in Patients with COVID-19. Journal of Personalized Medicine, 2022, 12, 162.	2.5	4
6	Prevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. European Journal of Clinical Pharmacology, 2022, 78, 879-886.	1.9	9
7	Inferior Vena Cava Edge Tracking Echocardiography: A Promising Tool with Applications in Multiple Clinical Settings. Diagnostics, 2022, 12, 427.	2.6	5
8	Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients. Biomedicines, 2022, 10, 424.	3.2	5
9	Health and Economic Impact of Atrial Fibrillation of Workers in Italy: Social Security Benefits. International Journal of Environmental Research and Public Health, 2022, 19, 1883.	2.6	1
10	Smartphone and new tools for atrial fibrillation diagnosis: evidence for clinical applicability. Minerva Cardiology and Angiology, 2022, 70, .	0.7	4
11	Inflammation and Cardiovascular Diseases in the Elderly: The Role of Epicardial Adipose Tissue. Frontiers in Medicine, 2022, 9, 844266.	2.6	19
12	Optimal anticoagulation in patients with atrial fibrillation and bioprosthetic heart valves. Kardiologia Polska, 2022, 80, 137-150.	0.6	3
13	Early evaluation of atrial high rate episodes using remote monitoring in pacemaker patients: Results from the RAPID study. Journal of Arrhythmia, 2022, 38, 213-220.	1.2	6
14	Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation. Medicina (Lithuania), 2022, 58, 399.	2.0	2
15	Effects of High Intensity Interval Training Rehabilitation Protocol after an Acute Coronary Syndrome on Myocardial Work and Atrial Strain. Medicina (Lithuania), 2022, 58, 453.	2.0	5
16	Pharmacokinetic determinants for the right dose of antiarrhythmic drugs. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-12.	3.3	1
17	Editorial: Neuromanagement and Neuromarketing. Frontiers in Psychology, 2022, 13, 864566.	2.1	1
18	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. Journal of Clinical Medicine, 2022, 11, 1945.	2.4	0

#	Article	IF	Citations
19	Add-on Therapy With Sacubitril/Valsartan and Clinical Outcomes in CRT-D Nonresponder Patients. Journal of Cardiovascular Pharmacology, 2022, 79, 472-478.	1.9	4
20	The prognostic role of interatrial block among COVIDâ€19 patients hospitalized in medicine wards. European Journal of Clinical Investigation, 2022, , e13781.	3.4	3
21	Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. Journal of Clinical Medicine, 2022, 11, 219.	2.4	6
22	Appropriate timing of electrophysiological study in myotonic dystrophy type 1: unsolved question. Europace, 2022, 24, 1036-1036.	1.7	2
23	New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress. Medicina (Lithuania), 2022, 58, 530.	2.0	12
24	2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders. Heart Rhythm, 2022, 19, e61-e120.	0.7	13
25	Cardioinhibitory syncope with asystole during nitroglycerin potentiated head up tilt test: prevalence and clinical predictors. Clinical Autonomic Research, 2022, 32, 167-173.	2.5	7
26	Air entrapment as a cause of S-ICD inappropriate shocks. Heart Rhythm, 2022, 19, 1751-1752.	0.7	2
27	COVID-19 Myocarditis: Prognostic Role of Bedside Speckle-Tracking Echocardiography and Association with Total Scar Burden. International Journal of Environmental Research and Public Health, 2022, 19, 5898.	2.6	16
28	Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry. Frontiers in Cardiovascular Medicine, 2022, 9, .	2.4	8
29	Management of older patients with unexplained, recurrent, traumatic syncope and bifascicular block: Implantable loop recorder versus empiric pacemaker implantationâ€"Results of a propensity-matched analysis. Heart Rhythm, 2022, 19, 1696-1703.	0.7	8
30	Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network. Journal of Clinical Medicine, 2022, 11, 3207.	2.4	1
31	Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. Journal of Clinical Medicine, 2022, 11, 3751.	2.4	5
32	Put out the fire: The pleiotropic anti-inflammatory action of non-vitamin K oral anticoagulants. Pharmacological Research, 2022, 182, 106335.	7.1	9
33	The role of inflammation and metabolic risk factors in the pathogenesis of calcific aortic valve stenosis. Aging Clinical and Experimental Research, 2021, 33, 1765-1770.	2.9	18
34	Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Scoreâ€"Matched Study. Cardiovascular Drugs and Therapy, 2021, 35, 1003-1007.	2.6	4
35	Role of electrophysiological evaluation for the best device choice to prevent sudden cardiac death in patients with Myotonic Dystrophy Type 1 and Emery Dreifuss Muscular Dystrophy. Trends in Cardiovascular Medicine, 2021, 31, e1-e2.	4.9	6
36	Fluoroscopy usage in contemporary interventional electrophysiology: Insights from a European registry. Clinical Cardiology, 2021, 44, 36-42.	1.8	14

#	Article	IF	Citations
37	Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thrombosis Research, 2021, 198, 34-39.	1.7	79
38	Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole. European Heart Journal, 2021, 42, 508-516.	2.2	69
39	Anticoagulation in Elderly Patients with Atrial Fibrillation Authors. , 2021, , 131-147.		0
40	Direct Oral Anticoagulation in Cancer Patients. , 2021, , 179-198.		0
41	Cardiac implantable electronic devices replacements in patients followed by remote monitoring during COVID-19 lockdown. European Heart Journal Digital Health, 2021, 2, 171-174.	1.7	5
42	Cardiac pacing procedures during coronavirus disease 2019 lockdown in Southern Italy: insights from Campania Region. Journal of Cardiovascular Medicine, 2021, 22, 857-859.	1.5	17
43	The â€œObesity Paradoxâ€•and the Use of NOAC. , 2021, , 149-178.		1
44	Cardiac Arrhythmias in Muscular Dystrophies Associated with Emerinopathy and Laminopathy: A Cohort Study. Journal of Clinical Medicine, 2021, 10, 732.	2.4	12
45	Direct Oral Anticoagulants Plasma Levels Measurement: Clinical Usefulness from Trials and Real-World Data. Seminars in Thrombosis and Hemostasis, 2021, 47, 150-160.	2.7	14
46	Tilt testing remains a valuable asset. European Heart Journal, 2021, 42, 1654-1660.	2.2	50
47	Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. Journal of Blood Medicine, 2021, Volume 12, 69-75.	1.7	16
48	Nursing Teleconsultation for the Outpatient Management of Patients with Cardiovascular Disease during COVID-19 Pandemic. International Journal of Environmental Research and Public Health, 2021, 18, 2087.	2.6	19
49	Regulation of Inflammation and Oxidative Stress by Formyl Peptide Receptors in Cardiovascular Disease Progression. Life, 2021, 11, 243.	2.4	16
50	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. Journal of Clinical Medicine, 2021, 10, 1569.	2.4	7
51	Prevalence of atrial fibrillation in myotonic dystrophy type 1: A systematic review. Neuromuscular Disorders, 2021, 31, 281-290.	0.6	8
52	Electrophysiological Study Prognostic Value and Long-Term Outcome in Drug-InducedÂTypeÂ1ÂBrugada Syndrome. JACC: Clinical Electrophysiology, 2021, 7, 1264-1273.	3.2	15
53	Cardiac Resynchronization Therapy in Patients with Heart Failure. Heart Failure Clinics, 2021, 17, 289-301.	2.1	3
54	Fondaparinux and bleeding risk in COVID-19: unsolved question. Thrombosis Research, 2021, 200, 128-129.	1.7	5

#	Article	IF	Citations
55	Appropriate ICD Interventions for Ventricular Arrhythmias Are Predicted by Higher Syntax Scores I and II in Patients with Ischemic Heart Disease. Journal of Clinical Medicine, 2021, 10, 1843.	2.4	0
56	Prevalence of Pulmonary Hypertension in an Unselected Community-Based Population: A Retrospective Echocardiographic Studyâ€"RES-PH Study. Journal of Personalized Medicine, 2021, 11, 489.	2.5	2
57	Left Ventricular Deformation and Vortex Analysis in Heart Failure: From Ultrasound Technique to Current Clinical Application. Diagnostics, 2021, 11, 892.	2.6	6
58	Pre-admission atrial fibrillation in COVID-19 patients: Prevalence and clinical impact. European Journal of Internal Medicine, 2021, 88, 133-135.	2.2	9
59	Non Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients Scheduled for Electrical Cardioversion: A Real-Life Propensity Score Matched Study. Journal of Blood Medicine, 2021, Volume 12, 413-420.	1.7	2
60	Clinical Differences between COVID-19 and a COVID-Like Syndrome. Journal of Clinical Medicine, 2021, 10, 2519.	2.4	6
61	Lead Abandonment and Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) Implantation in a Cohort of Patients With ICD Lead Malfunction. Frontiers in Cardiovascular Medicine, 2021, 8, 692943.	2.4	6
62	Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports. Journal of Cardiovascular Pharmacology, 2021, 78, e20-e29.	1.9	17
63	Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study. Journal of Cardiovascular Pharmacology, 2021, 78, e94-e100.	1.9	11
64	Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009811.	4.8	33
65	Clinical conditions and echocardiographic parameters associated with mortality in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13638.	3.4	26
66	Heart rate distribution in paced and non-paced patients with severe recurrent reflex syncope and tilt-induced asystole: Findings from the BIOSync CLS study. International Journal of Cardiology, 2021, 335, 52-54.	1.7	6
67	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 2021, 13, 1720.	3.3	9
68	Impaired myocardial work efficiency in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2021, 22, 1312-1320.	1.2	28
69	Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients. Expert Review of Clinical Pharmacology, 2021, 14, 1289-1294.	3.1	6
70	Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. Clinical Therapeutics, 2021, 43, e255-e263.	2.5	19
71	Edoxaban (LIXIANAÂ®) in the treatment of venous thromboembolism. Future Cardiology, 2021, 17, 779-791.	1.2	1
72	The Impact of COVID-19 Outbreak on Syncope Units Activities in Italy: A Report from the Italian Multidisciplinary Working Group on Syncope (GIMSI). International Journal of Environmental Research and Public Health, 2021, 18, 9194.	2.6	8

#	Article	IF	Citations
73	Brugada syndrome and COVID-19 vaccines. Europace, 2021, 23, 1871-1872.	1.7	10
74	Potential role of an athlete-focused echocardiogram in sports eligibility. World Journal of Cardiology, 2021, 13, 271-297.	1.5	21
75	Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: AÂMeta-analysis. CJC Open, 2021, 3, S202-S208.	1.5	8
76	Myocardial Work by Echocardiography: Principles and Applications in Clinical Practice. Journal of Clinical Medicine, 2021, 10, 4521.	2.4	38
77	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Lithuania), 2021, 57, 997.	2.0	9
78	Watch the P wave in COVID-19 patients: the interatrial block. Journal of Cardiovascular Medicine, 2021, 22, e51.	1.5	3
79	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization. International Journal of Environmental Research and Public Health, 2021, 18, 102.	2.6	15
80	The Role of Multimodality Imaging in Athleteâ€™s Heart Diagnosis: Current Status and Future Directions. Journal of Clinical Medicine, 2021, 10, 5126.	2.4	20
81	Prognostic Value of Electrophysiologic Study in Drug-Induced Brugada Syndrome: Caution is Always a Must. American Journal of Cardiology, 2021, , .	1.6	3
82	Unmet needs on the management of COVID-19 vaccination in patients with neuromuscular disorders. Acta Myologica, 2021, 40, 113-115.	1.5	1
83	Prognostic Implications of Right Ventricular Function and Pulmonary Pressures Assessed by Echocardiography in Hospitalized Patients with COVID-19. Journal of Personalized Medicine, 2021, 11, 1245.	2.5	7
84	Single-Chamber Leadless Cardiac Pacemaker in Patients Without Atrial Fibrillation: Findings From Campania Leadless Registry. Frontiers in Cardiovascular Medicine, 2021, 8, 781335.	2.4	2
85	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses, 2021, 13, 2486.	3.3	10
86	659â€ƒMyocardial infarcion and ischaemic stroke in a COVID-19 patient: nothing happens by chance. European Heart Journal Supplements, 2021, 23, .	0.1	0
87	604â€ƒEchocardiographic assessment of right ventricular function and pulmonary pressures in hospitalized patients with COVID-19. European Heart Journal Supplements, 2021, 23, .	0.1	0
88	618â€ƒClinical conditions and echocariographic parameters associated with mortality in COVID-19. European Heart Journal Supplements, 2021, 23, .	0.1	0
89	Cardiac Pacing in Cardioinhibitory Reflex Syncope: Clinical Use of Closed-loop Stimulation. Arrhythmia and Electrophysiology Review, 2021, 10, 244-249.	2.4	5
90	244â€ƒPrevalence and clinical predictors of inappropriate direct oral anticoagulant dosage in octagenarians with atrial fibrillation. European Heart Journal Supplements, 2021, 23, .	0.1	0

#	Article	IF	Citations
91	622â€ƒLong term prognostic impact of right ventricular dysfunction in patients with COVID-19. European Heart Journal Supplements, 2021, 23, .	0.1	0
92	Editorial commentary: Myotonic Dystrophy: The â€œright weaponsâ€•to fight the long battle against sudden cardiac death. Trends in Cardiovascular Medicine, 2020, 30, 239-240.	4.9	1
93	Validation of the echocardiographic assessment of epicardial adipose tissue thickness at the Rindfleisch fold for the prediction of coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 99-105.	2.6	26
94	Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. Journal of Thrombosis and Thrombolysis, 2020, 49, 42-53.	2.1	31
95	Prevalence of Left Ventricular Systolic Dysfunction in Myotonic Dystrophy Type 1: A Systematic Review. Journal of Cardiac Failure, 2020, 26, 849-856.	1.7	18
96	The association between atrial fibrillation and Alzheimer's disease: fact or fallacy? A systematic review and meta-analysis. Journal of Cardiovascular Medicine, 2020, 21, 106-112.	1.5	24
97	The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacological Research, 2020, 151, 104521.	7.1	50
98	Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. Journal of Cardiovascular Pharmacology, 2020, 76, 369-371.	1.9	24
99	Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. American Journal of Cardiology, 2020, 134, 83-90.	1.6	18
100	Nonâ€vitamin K vs vitamin K oral anticoagulants in patients agedÂ>Â80 year with atrial fibrillation and low body weight. European Journal of Clinical Investigation, 2020, 50, e13335.	3.4	19
101	Blood Targets of Adjuvant Drugs Against COVID19 . Journal of Blood Medicine, 2020, Volume 11, 237-241.	1.7	7
102	Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study. Frontiers in Medicine, 2020, 7, 569567.	2.6	21
103	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 582348.	3.5	15
104	Clinical characteristics and prognosis of hospitalized COVIDâ€19 patients with incident sustained tachyarrhythmias: A multicenter observational study. European Journal of Clinical Investigation, 2020, 50, e13387.	3.4	54
105	Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications. Journal of Cardiovascular Pharmacology, 2020, 76, 138-145.	1.9	41
106	Arrhythmogenic syncope leading to cardiac rhythm management procedures during COVID-19 lockdown. Expert Review of Medical Devices, 2020, 17, 1207-1210.	2.8	7
107	The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. Journal of Clinical Medicine, 2020, 9, 3926.	2.4	12
108	Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. Journal of Clinical Medicine, 2020, 9, 1371.	2.4	63

#	Article	IF	Citations
109	Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. Journal of Clinical Medicine, 2020, 9, 1621.	2.4	13
110	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacological Research, 2020, 159, 104965.	7.1	97
111	COVID-19 and cardiac implantable electronic device remote monitoring: crocodile tears or new opportunity?. Expert Review of Medical Devices, 2020, 17, 471-472.	2.8	13
112	Stroke, Dementia, and Atrial Fibrillation: From Pathophysiologic Association to Pharmacological Implications. Medicina (Lithuania), 2020, 56, 227.	2.0	6
113	Apixaban in a Morbid Obese Patient with Atrial Fibrillation: A Clinical Experience Using the Plasmatic Drug Evaluation . Journal of Blood Medicine, 2020, Volume 11, 77-81.	1.7	7
114	Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	9
115	Echocardiographic Epicardial Adipose Tissue Thickness for Risk Stratification of Patients With Heart Failure. Frontiers in Physiology, 2020, 11, 43.	2.8	14
116	In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments . Journal of Blood Medicine, 2020, Volume 11, 185-190.	1.7	11
117	Atrial Fibrillation and Mitral Regurgitation: Clinical Performance of Direct Oral Anticoagulants in a Real-World Setting. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 564-569.	2.0	3
118	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. Journal of Clinical Medicine, 2020, 9, 1944.	2.4	36
119	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. Europace, 2020, 22, 833-838.	1.7	11
120	Impact on All-Cause and Cardiovascular Mortality of Cardiac Implantable Electronic Device Complications. JACC: Clinical Electrophysiology, 2020, 6, 382-392.	3.2	24
121	The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator. Journal of Clinical Medicine, 2020, 9, 1111.	2.4	26
122	Anti-arrhythmic properties of non-antiarrhythmic medications. Pharmacological Research, 2020, 156, 104762.	7.1	14
123	Clinical Performance of Nonvitamin K Antagonist Oral Anticoagulants in Real-World Obese Patients with Atrial Fibrillation. Seminars in Thrombosis and Hemostasis, 2020, 46, 970-976.	2.7	11
124	Association of atrial fibrillation and left atrial volume index with mortality in patients with COVID-19 pneumonia. European Journal of Preventive Cardiology, 2020, , .	1.8	4
125	Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study. Journal of Clinical Medicine, 2020, 9, 4134.	2.4	28
126	Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate. Medicina (Lithuania), 2020, 56, 506.	2.0	12

#	Article	IF	Citations
127	Antithrombotic drugs with adjuvant action against COVID-19. Italian Journal of Medicine, 2020, 14, 241-244.	0.3	1
128	ST-elevation during head up tilt test: a challenging case in syncope unit. Monaldi Archives for Chest Disease, 2020, 90, .	0.6	2
129	Atrial Fibrillation and Malignancy: The Clinical Performance of Nonâ€“Vitamin K Oral Anticoagulantsâ€”A Systematic Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 205-214.	2.7	30
130	Ablation of Atrial Flutter with Zero Fluoroscopy Approach. , 2019, , 111-128.		0
131	SERUM cardiacâ€specific biomarkers and atrial fibrillation in myotonic dystrophy type I. Journal of Cardiovascular Electrophysiology, 2019, 30, 2914-2919.	1.7	3
132	Subclinical Atrial Fibrillation and Risk of Stroke: Past, Present and Future. Medicina (Lithuania), 2019, 55, 611.	2.0	21
133	Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Scoreâ€“Matched Cohort Study. Clinical Therapeutics, 2019, 41, 1598-1604.	2.5	26
134	Safety and Efficacy of Triple Antithrombotic Therapy with Dabigatran versus Vitamin K Antagonist in Atrial Fibrillation Patients: A Pilot Study. BioMed Research International, 2019, 2019, 1-6.	1.9	6
135	Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study. American Journal of Cardiovascular Drugs, 2019, 19, 421-427.	2.2	17
136	Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients. Pharmacological Research, 2019, 143, 133-142.	7.1	5
137	Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy. Pharmacological Research, 2019, 143, 27-32.	7.1	6
138	Persistence on apixaban in atrial fibrillation patients: a retrospective multicentre study. Journal of Cardiovascular Medicine, 2019, 20, 66-73.	1.5	14
139	Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Clinical Therapeutics, 2019, 41, 2549-2557.	2.5	40
140	Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late. Journal of Cardiovascular Pharmacology, 2019, 73, 207-214.	1.9	33
141	Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures. Journal of Cardiovascular Pharmacology, 2019, 75, 1.	1.9	10
142	Arrhythmias and Sudden Cardiac Death in Beta-Thalassemia Major Patients: Noninvasive Diagnostic Tools and Early Markers. Cardiology Research and Practice, 2019, 2019, 1-8.	1.1	11
143	The Role of Cardiovascular and Metabolic Comorbidities in the Link between Atrial Fibrillation and Cognitive Impairment: An Appraisal of Current Scientific Evidence. Medicina (Lithuania), 2019, 55, 767.	2.0	10
144	Seasonal trend of ventricular arrhythmias in a nationwide remote monitoring database of implantable defibrillators and cardiac resynchronization devices. International Journal of Cardiology, 2019, 275, 104-106.	1.7	6

#	Article	IF	Citations
145	Are there real benefits to implanting cardiac devices in patients with end-stage dilated dystrophinopathic cardiomyopathy? Review of literature and personal results. Acta Myologica, 2019, 38, 1-7.	1.5	7
146	Subcutaneous implantable cardioverter defibrillator eligibility according to a novel automated screening tool and agreement with the standard manual electrocardiographic morphology tool. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 61-67.	1.3	27
147	Bachmann bundle pacing reduces atrial electromechanical delay in type 1 myotonic dystrophy patients. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 229-236.	1.3	6
148	Interatrial block to predict atrial fibrillation in myotonic dystrophy type 1. Neuromuscular Disorders, 2018, 28, 327-333.	0.6	11
149	Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study. Journal of Thrombosis and Thrombolysis, 2018, 45, 206-212.	2.1	22
150	ACE inhibition to slow progression of myocardial fibrosis in muscular dystrophies. Trends in Cardiovascular Medicine, 2018, 28, 330-337.	4.9	29
151	Effects of defibrillation shock in patients implanted with a subcutaneous defibrillator: a biomarker study. Europace, 2018, 20, f233-f239.	1.7	10
152	Nonvitamin K Antagonist Oral Anticoagulants Use in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves/Prior Surgical Valve Repair: A Multicenter Clinical Practice Experience. Seminars in Thrombosis and Hemostasis, 2018, 44, 364-369.	2.7	38
153	Effect of dual-chamber minimal ventricular pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: A prospective, randomized, single-blind, crossover study. Heart Rhythm, 2018, 15, 962-968.	0.7	10
154	Effects of closed-loop stimulation vs. DDD pacing on haemodynamic variations and occurrence of syncope induced by head-up tilt test in older patients with refractory cardioinhibitory vasovagal syncope: the Tilt test-Induced REsponse in Closed-loop Stimulation multicentre, prospective, single blind, randomized study. Europace, 2018, 20, 859-866.	1.7	48
155	Use of Nonâ€“Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Malignancy: Clinical Practice Experience in a Single Institution and Literature Review. Seminars in Thrombosis and Hemostasis, 2018, 44, 370-376.	2.7	39
156	Glomerular filtration rate: A prognostic marker in atrial fibrillationâ€”A subanalysis of the AntiThrombotic Agents Atrial Fibrillation. Clinical Cardiology, 2018, 41, 1570-1577.	1.8	8
157	Optimal left ventricular lead placement for cardiac resynchronization therapy in postmyocardial infarction patients. Future Cardiology, 2018, 14, 215-224.	1.2	2
158	Does cardiac pacing reduce syncopal recurrences in cardioinhibitory vasovagal syncope patients selected with head-up tilt test? Analysis of a 5-year follow-up database. International Journal of Cardiology, 2018, 270, 149-153.	1.7	17
159	Remote Monitoring of Atrial High Rate Episodes in Pacemaker Patients. The Rapid Study Design. Journal of Atrial Fibrillation, 2018, 11, 2075.	0.5	3
160	Atrial fibrillation in beta thalassemia major: how to perform effective screening and early detection. Hematology, 2017, 22, 368-369.	1.5	1
161	Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. Journal of Clinical Pharmacology, 2017, 57, 924-930.	2.0	10
162	Temperament and character personality dimensions in nitrate-tilt-induced vasovagal syncope patients. Hellenic Journal of Cardiology, 2017, 58, 411-416.	1.0	7

#	Article	IF	Citations
163	The role of the atrial electromechanical delay in predicting atrial fibrillation in beta-thalassemia major patients. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 147-157.	1.3	20
164	The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1. JAMA Cardiology, 2017, 2, 1044.	6.1	7
165	Which is the true epidemiology of left ventricular dysfunction in patients with myotonic dystrophy type 1?. Journal of the Chinese Medical Association, 2017, 80, 740-741.	1.4	3
166	The clinical performance of dabigatran in the Italian real-life experience. Journal of Cardiovascular Medicine, 2017, 18, 922-923.	1.5	16
167	NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world. International Journal of Cardiology, 2017, 249, 179-183.	1.7	60
168	Arrhythmic risk evaluation in myotonic dystrophy: the importance of selection criteria and methodological approach. Clinical Autonomic Research, 2017, 27, 203-204.	2.5	4
169	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Therapeutic Advances in Drug Safety, 2017, 8, 67-75.	2.4	40
170	The role of P-wave dispersion in dystrophic and thalassemic cardiomyopathy. JRSM Cardiovascular Disease, 2017, 6, 204800401666301.	0.7	1
171	Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study. Minerva Cardiology and Angiology, 2017, 66, 1-5.	0.7	8
172	Atrial fibrillation risk evaluation in patients with generalised anxiety disorders: the role of electrocardiographic parameters. Commentary to the article: â€œAtrial electromechanical delay analysed by tissue Doppler echocardiographyâ€¦". Kardiologia Polska, 2017, 75, 632-633.	0.6	1
173	Electrocardiographic Presentation, Cardiac Arrhythmias, and Their Management in Î²â€Thalassemia Major Patients. Annals of Noninvasive Electrocardiology, 2016, 21, 335-342.	1.1	34
174	Impact of Continuous Positive Airway Pressure Therapy on Atrial Electromechanical Delay in Obesityâ€Hypoventilation Syndrome Patients. Journal of Cardiovascular Electrophysiology, 2016, 27, 327-334.	1.7	22
175	Which Is the True Epidemiology of Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients?. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1418-1419.	1.2	8
176	Letter to the Editorâ€”Prevalence of interatrial block during lifetime. Heart Rhythm, 2016, 13, e90-e91.	0.7	4
177	The importance of a correct methodological approach for the arrhythmic risk evaluation in beta thalassemia major patients. International Journal of Cardiology, 2016, 225, 107-108.	1.7	7
178	A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience. International Journal of Cardiology, 2016, 224, 454-455.	1.7	21
179	The Role of the Atrial Electromechanical Delay in Predicting Atrial Fibrillation in Myotonic Dystrophy Type 1 Patients. Journal of Cardiovascular Electrophysiology, 2016, 27, 65-72.	1.7	32
180	Sudden cardiac death in neuromuscolar disorders: Time to establish shared protocols for cardiac pacing. International Journal of Cardiology, 2016, 207, 284-285.	1.7	19

#	Article	IF	Citations
181	Polycystic ovary syndrome and arrhythmic risk: the role of comorbidities and the prevalence of interatrial block. Anatolian Journal of Cardiology, 2016, 16, 730.	0.9	0
182	Increased heterogeneity of ventricular repolarization in myotonic dystrophy type 1 population. Acta Myologica, 2016, 35, 100-106.	1.5	8
183	Voltage-directed cavo-tricuspid isthmus ablation using a novel ablation catheter mapping technology in a myotonic dystrophy type I patient. Acta Myologica, 2016, 35, 109-113.	1.5	3
184	Atrial Septal Aneurysms and Supraventricular Arrhythmias: The Role of Atrial Electromechanical Delay. Echocardiography, 2015, 32, 1504-1514.	0.9	21
185	Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. Medical Devices: Evidence and Research, 2015, 8, 103.	0.8	7
186	ICD role in preventing sudden cardiac death in Emery-Dreifuss muscular dystrophy with preserved myocardial function: 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy. Europace, 2015, 17, 337-337.	1.7	21
187	Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry. International Journal of Cardiology, 2015, 184, 283-284.	1.7	22
188	Cardiopulmonary resuscitation in pectus excavatum patients: Is it time to say more?. Resuscitation, 2015, 88, e5-e6.	3.0	7
189	A Systematic Review and Meta-analysis of the Association Between Implantable Cardioverter-Defibrillator Shocks and Long-term Mortality. Canadian Journal of Cardiology, 2015, 31, 270-277.	1.7	69
190	Which Hemodynamic Parameter Predicts Nitroglycerinâ€Potentiated Headâ€Up Tilt Test Response?. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 507-513.	1.2	7
191	Impact of continuous positive airway pressure therapy on atrial electromechanical delay in obesity-hypoventilation syndrome patients. , 2015, , .		0
192	Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis. Indian Pacing and Electrophysiology Journal, 2014, 14, 121-132.	0.6	26
193	Adenosine-induced sinus tachycardia in a patient with Myotonic Dystrophy type 1. Acta Myologica, 2014, 33, 104-6.	1.5	9
194	Far field R-wave sensing in Myotonic Dystrophy type 1: right atrial appendage versus Bachmann's bundle region lead placement. Acta Myologica, 2014, 33, 94-9.	1.5	11
195	Ventricular fibrillation induced by coagulating mode bipolar electrocautery during pacemaker implantation in Myotonic Dystrophy type 1 patient. Acta Myologica, 2014, 33, 149-51.	1.5	10
196	The effect of atrial preference pacing on atrial fibrillation electrophysiological substrate in Myotonic Dystrophy type 1 population. Acta Myologica, 2014, 33, 127-35.	1.5	11
197	The effect of dual-chamber closed-loop stimulation on syncope recurrence in healthy patients with tilt-induced vasovagal cardioinhibitory syncope: a prospective, randomised, single-blind, crossover study. Heart, 2013, 99, 1609-1613.	2.9	52
198	Does Left Atrial Appendage Closure with a Cardiac Plug System Reduce the Stroke Risk in Nonvalvular Atrial Fibrillation Patients? A Singleâ€Center Case Series. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 347-353.	1.2	21

#	Article	IF	Citations
199	Does a high percentage of right ventricular pacing influence the incidence of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients?. Kardiologia Polska, 2013, 71, 1147-1153.	0.6	21
200	Atrial fibrillation burden in Myotonic Dystrophy type 1 patients implanted with dual chamber pacemaker: the efficacy of the overdrive atrial algorithm at 2 year follow-up. Acta Myologica, 2013, 32, 142-7.	1.5	18
201	The effect of atrial preference pacing on paroxysmal atrial fibrillation incidence in myotonic dystrophy type 1 patients: a prospective, randomized, single-bind cross-over study. Europace, 2012, 14, 486-489.	1.7	25
202	The Main Determinant of Hypotension in Nitroglycerine Tiltâ€Induced Vasovagal Syncope. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 739-748.	1.2	20
203	Heterogeneity of Ventricular Repolarization in Newborns With Severe Aortic Coarctation. Pediatric Cardiology, 2012, 33, 302-306.	1.3	26
204	Increased dispersion of ventricular repolarization in emery dreifuss muscular dystrophy patients. Medical Science Monitor, 2012, 18, CR643-CR647.	1.1	34
205	Early onset â€œelectricalâ€•heart failure in myotonic dystrophy type 1 patient: the role of ICD biventricular pacing. Anatolian Journal of Cardiology, 2012, 12, 517-9.	0.4	22
206	Right atrial preference pacing algorithm in the prevention of paroxysmal atrial fibrillation in myotonic dystrophy type 1 patients: a long term follow-up study. Acta Myologica, 2012, 31, 139-43.	1.5	21
207	Cardiac resynchronization improves heart failure in one patient with myotonic dystrophy type 1. A case report. Acta Myologica, 2012, 31, 154-5.	1.5	15
208	Regional and transmural dispersion of repolarisation in patients with Emery-Dreifuss muscular dystrophy. Kardiologia Polska, 2012, 70, 1154-9.	0.6	27
209	Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy. PLoS ONE, 2011, 6, e24729.	2.5	19
210	P-Wave Duration and Dispersion in Patients with Emery-Dreifuss Muscular Dystrophy. Journal of Investigative Medicine, 2011, 59, 1151-1154.	1.6	27
211	Dispersion of repolarization and beta-thalassemia major: the prognostic role of QT and JT dispersion for identifying the high-risk patients for sudden death. European Journal of Haematology, 2011, 86, 324-331.	2.2	51
212	Early electrocardiographic evaluation of atrial fibrillation risk in beta-thalassemia major patients. International Journal of Hematology, 2011, 93, 446-451.	1.6	31
213	Ginkgo biloba. Journal of Postgraduate Medicine, 2011, 57, 221.	0.4	9
214	Increased Heterogenity of Ventricular Repolarization in Obese Nonhypertensive Children. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 1533-1539.	1.2	29
215	Autonomic Nervous System Modulation before the Onset of Sustained Atrioventricular Nodal Reentry Tachycardia. Annals of Noninvasive Electrocardiology, 2010, 15, 49-55.	1.1	12
216	Which parameters describe the electrophysiological properties of successful slow pathway RF ablation in patients with common atrioventricular nodal reentrant tachycardia?. Anatolian Journal of Cardiology, 2010, 10, 126-129.	0.4	3

#	Article	IF	Citations
217	Does Bachmann's bundle pacing prevent atrial fibrillation in myotonic dystrophy type 1 patients? A 12 months follow-up study. Europace, 2010, 12, 1219-1223.	1.7	32
218	Early onset of cardiomyopathy and primary prevention of sudden death in X-linked Emeryâ€“Dreifuss muscular dystrophy. Neuromuscular Disorders, 2010, 20, 174-177.	0.6	27
219	The Impact of Selection Criteria of Obese Patients on Evaluation of Heart Rate Variability Following Bariatric Surgery Weight Loss. Obesity Surgery, 2009, 19, 397-398.	2.1	6
220	Right Atrial Appendage Versus Bachmann's Bundle Stimulation: A Twoâ€Year Comparative Study of Electrical Parameters in Myotonic Dystrophy Typeâ€1 Patients. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1191-1196.	1.2	22
221	Superselective cannulation of coronary sinus branch with telescopic system during left ventricular lead placement. Acta Biomedica, 2009, 80, 153-5.	0.3	1
222	Severe Obesity and P-Wave Dispersion: The Effect of Surgically Induced Weight Loss. Obesity Surgery, 2008, 18, 90-96.	2.1	44
223	Optimal Site for Atrial Lead Implantation in Myotonic Dystrophy Patients: The Role of Bachmann's Bundle Stimulation. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1463-1466.	1.2	21
224	Heart rate variability, obesity, and bariatric-induced weight loss: the importance of selection criteria. Metabolism: Clinical and Experimental, 2008, 57, 1622.	3.4	3
225	Coronary sinus spasm during left ventricular lead implantation for biventricular pacing. Europace, 2007, 9, 528-530.	1.7	3
226	Giant coronary sinus in patient with double superior vena cava demonstrated by multislice computed tomography. Journal of Cardiovascular Medicine, 2007, 8, 1080-1082.	1.5	0
227	Effect of Weight Loss following Bariatric Surgery on Myocardial Dispersion of Repolarization in Morbidly Obese Patients. Obesity Surgery, 2007, 17, 857-865.	2.1	53
228	Sympathovagal balance analysis in idiopathic postural orthostatic tachycardia syndrome. Acta Biomedica, 2007, 78, 133-8.	0.3	6
229	Biventricular Pacing and Heterogeneity of Ventricular Repolarization in Heart Failure Patients. Heart International, 2006, 2, 182618680600200.	1.4	0
230	Influence of biventricular pacing on myocardial dispersion of repolarization in dilated cardiomyopathy patients. Europace, 2006, 8, 502-505.	1.7	30
231	Biventricular pacing and heterogeneity of ventricular repolarization in heart failure patients. Heart International, 2006, 2, 27.	1.4	3
232	Heart rate variability analysis in postural orthostatic tachycardia syndrome: a case report. Heart International, 2006, 2, 126.	1.4	1
233	Azithromycin-induced QT prolongation in elderly patient. Acta Biomedica, 2006, 77, 30-2.	0.3	42
234	Effects of COVIDâ€19 lockdown on arrhythmias in patients with implantable cardioverterâ€defibrillators in southern Italy. Journal of Arrhythmia, 0, , .	1.2	1

#	Article	IF	Citations
235	Epicardial Adipose Tissue and Cardiac Arrhythmias: Focus on Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	19